Probabilistic sensitivity analysis in health economics

Health economic evaluations have recently become an important part of the clinical and medical research process and have built upon more advanced statistical decision-theoretic foundations. In some contexts, it is officially required that uncertainty about both parameters and observable variables be properly taken into account, increasingly often by means of Bayesian methods. Among these, probabilistic sensitivity analysis has assumed a predominant role. The objective of this article is to review the problem of health economic assessment from the standpoint of Bayesian statistical decision theory with particular attention to the philosophy underlying the procedures for sensitivity analysis.

[1]  K Claxton,et al.  Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. , 1999, Health economics.

[2]  G Parmigiani,et al.  Measuring uncertainty in complex decision analysis models , 2002, Statistical methods in medical research.

[3]  Matt Stevenson,et al.  Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. , 2007, Health economics.

[4]  M. Drummond,et al.  Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.

[5]  H. Sacks,et al.  The Efficacy of Influenza Vaccine in Elderly Persons , 1995, Annals of Internal Medicine.

[6]  Karl Claxton,et al.  An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[8]  K. Nichol,et al.  Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. , 2003, Vaccine.

[9]  Ronald A. Howard,et al.  Information Value Theory , 1966, IEEE Trans. Syst. Sci. Cybern..

[10]  Alan Brennan,et al.  Efficient computation of partial expected value of sample information using Bayesian approximation. , 2007, Journal of health economics.

[11]  G. Loomes,et al.  The use of QALYs in health care decision making. , 1989, Social science & medicine.

[12]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy adults. , 2000, The Cochrane database of systematic reviews.

[13]  B. M. Hill,et al.  Theory of Probability , 1990 .

[14]  D. Spiegelhalter,et al.  Incorporation of uncertainty in health economic modelling studies , 2012, PharmacoEconomics.

[15]  A O'Hagan,et al.  A framework for cost-effectiveness analysis from clinical trial data. , 2001, Health economics.

[16]  H Raiffa,et al.  Decision Analysis: Introductory Lectures on Choices under Uncertainty. , 1969 .

[17]  Paul Kind,et al.  EQ-5D concepts and methods : a developmental history , 2005 .

[18]  B J O'Brien,et al.  Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.

[19]  Jeremy E. Oakley,et al.  Decision-Theoretic Sensitivity Analysis for Complex Computer Models , 2009, Technometrics.

[20]  Karl Claxton,et al.  Probabilistic analysis and computationally expensive models: Necessary and required? , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[21]  Bas Groot Koerkamp,et al.  Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  Anthony O’Hagan,et al.  Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio , 2000, PharmacoEconomics (Auckland).

[23]  A O'Hagan,et al.  Bayesian cost‐effectiveness analysis from clinical trial data , 2001, Statistics in medicine.

[24]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[26]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[27]  A. Briggs,et al.  Statistical Analysis of Cost-effectiveness Data: Willan/Statistical Analysis of Cost-effectiveness Data , 2006 .

[28]  A E Ades,et al.  Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  Andrew H. Briggs,et al.  Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.

[30]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[31]  B. McNeil,et al.  Probabilistic Sensitivity Analysis Using Monte Carlo Simulation , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.

[32]  Simon G Thompson,et al.  Accounting for uncertainty in health economic decision models by using model averaging , 2009, Journal of the Royal Statistical Society. Series A,.

[33]  David J Spiegelhalter,et al.  Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.

[34]  Eric J. Johnson,et al.  Decisions Under Uncertainty: Psychological, Economic, and Neuroeconomic Explanations of Risk Preference , 2009 .

[35]  Gordon B. Hazen,et al.  Sensitivity Analysis and the Expected Value of Perfect Information , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  D M Berwick,et al.  Broadening the view of evidence-based medicine , 2005, Quality and Safety in Health Care.

[37]  M. A. Best Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[38]  A. O'Hagan,et al.  Probabilistic sensitivity analysis of complex models: a Bayesian approach , 2004 .

[39]  L. M. M.-T. Theory of Probability , 1929, Nature.

[40]  S. Michael Malinconico,et al.  Decisions under Uncertainty. , 1984 .

[41]  A. Sutton,et al.  The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. , 2006, Vaccine.

[42]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[43]  Gordon B. Hazen,et al.  A Bayesian approach to sensitivity analysis. , 1999, Health economics.

[44]  P. Jones Making Decisions , 1971, Nature.

[45]  Ron Goeree,et al.  Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[46]  Gianluca Baio,et al.  A Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes , 2012, PharmacoEconomics.

[47]  A H Briggs,et al.  A Bayesian approach to stochastic cost-effectiveness analysis. , 1999, Health economics.

[48]  Howard Raiffa,et al.  Decision analysis: introductory lectures on choices under uncertainty. 1968. , 1969, M.D.Computing.

[49]  M. Lean,et al.  Translational research , 2008, BMJ : British Medical Journal.

[50]  Stefano Tarantola,et al.  Sensitivity Analysis in Practice: A Guide to Assessing Scientific Models , 2004 .

[51]  Eric R. Ziegel,et al.  Modeling in Medical Decision Making , 2002, Technometrics.

[52]  Andrew Briggs,et al.  Statistical Analysis of Cost-Effectiveness Data , 2006 .

[53]  M C Weinstein,et al.  Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. , 2001, International journal of technology assessment in health care.

[54]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.